The MCP-1 increase was significantly lower in the treated groups compared to the BD group: Coversin group 4227 pg/mL (1663–6792) (p = 0.001), anti-CD14 group 1284 pg/mL (433–2135) (p = 0.0004) and the dual treatment group 2215 pg/mL (555–3875) (p = 0.0006) (Fig. 2A). Here, CCL2 is linked to Behcet disease.